FRA
EW icon

Frank Rimerman Advisors’s Edwards Lifesciences EW Stock Holding History

Frank Rimerman Advisors’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$580K Sell
6,412
-107
-2% -$8.96K 0.03% 378
2026
Q1 		$522K Buy
6,519
+9
+0.1% +$742 0.03% 368
2025
Q4 		$555K Buy
6,510
+414
+7% +$34K 0.04% 355
2025
Q3 		$474K Buy
6,096
+102
+2% +$7.97K 0.03% 382
2025
Q2 		$469K Sell
5,994
-240
-4% -$17.9K 0.03% 363
2025
Q1 		$452K Sell
6,234
-532
-8% -$38.1K 0.04% 333
2024
Q4 		$501K Buy
6,766
+1,392
+26% +$97.4K 0.04% 310
2024
Q3 		$355K Sell
5,374
-1,421
-21% -$103K 0.03% 389
2024
Q2 		$628K Buy
6,795
+6,774
+32,257% +$600K 0.04% 295
2024
Q1 		$2.01K Hold
21
– – ﹤0.01% 284
2023
Q4 		$1.6K Buy
+21
New +$1.46K ﹤0.01% 279

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Frank Rimerman Advisors's EW Position: Q2 2026 in Review

Frank Rimerman Advisors reduced its Edwards Lifesciences (EW) stake by 1.6% in Q2 2026, selling an estimated $8.96K and leaving 6,412 shares worth $580K. The position accounts for 0.03% of the portfolio, ranked #378.

Frank Rimerman Advisors first reported a position in EW in Q4 2023 and has held it in 11 quarters since. The position peaked at $628K in Q2 2024. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Frank Rimerman Advisors held 6,412 shares of Edwards Lifesciences worth $580K as of Q2 2026.
  • Frank Rimerman Advisors sold 107 Edwards Lifesciences shares in Q2 2026, an estimated $8.96K.
  • Edwards Lifesciences made up 0.03% of Frank Rimerman Advisors's portfolio in Q2 2026, its #378 holding.
  • Frank Rimerman Advisors first reported a position in Edwards Lifesciences in Q4 2023 and has held it in 11 quarters since.
  • Frank Rimerman Advisors's Edwards Lifesciences position peaked at $628K in Q2 2024.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Frank Rimerman Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.